SE0100857D0 - Treatment of tumors - Google Patents
Treatment of tumorsInfo
- Publication number
- SE0100857D0 SE0100857D0 SE0100857A SE0100857A SE0100857D0 SE 0100857 D0 SE0100857 D0 SE 0100857D0 SE 0100857 A SE0100857 A SE 0100857A SE 0100857 A SE0100857 A SE 0100857A SE 0100857 D0 SE0100857 D0 SE 0100857D0
- Authority
- SE
- Sweden
- Prior art keywords
- alpha
- androstane
- medicament
- derivatives
- androstene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0014—Androstane derivatives substituted in position 17 alfa, not substituted in position 17 beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (androstane- or pregnane-) in the manufacture of a medicament for the treatment of a benign and/or malignant tumour, which medicament is capable of interrupting disturbances in Wnt-signaling, such as cell-cycle arrest in G1-phase, and/or providing an angiostatic effect. Examples of such steroid derivatives are DELTA -5-androstene-17 alpha -ol, androstane-17 alpha -ol-pregnane-17 alpha -ol or pregnane-17 alpha -ol derivatives. In a further aspect, the invention relates to a method of producing a medicament for the treatment of a benign and/or malignant tumour and/or an inflammatory condition comprising the steps of contacting 5-androstane-3ss,17 alpha -diol or androstane-3ss alpha -diol, an enzyme and a sulfotransferase to provide 5-androstene-17 alpha -ol-3ss-sulfate or corresponding androstane derivative (17 alpha -AEDS or 17-AADS); and mixing the 17 alpha -AEDS or 17 alpha -AADS so produced with a suitable carrier; whereby a medicament which is capable of acting as a ligand to perox-isome proliferator-activated receptor- gamma (PPAR gamma ) is produced.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0100857A SE0100857D0 (en) | 2001-03-13 | 2001-03-13 | Treatment of tumors |
AU2002237613A AU2002237613B2 (en) | 2001-03-13 | 2002-03-11 | Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
EP02704017A EP1379542A2 (en) | 2001-03-13 | 2002-03-11 | Treatment of tumours |
PCT/SE2002/000443 WO2002072003A2 (en) | 2001-03-13 | 2002-03-11 | Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
JP2002570963A JP2004524325A (en) | 2001-03-13 | 2002-03-11 | Use of steroid derivatives for the treatment of benign and / or malignant tumors |
CA002440973A CA2440973A1 (en) | 2001-03-13 | 2002-03-11 | Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
US10/658,125 US20050192262A1 (en) | 2001-03-13 | 2003-09-09 | Treatment of tumours |
US11/609,643 US20070111973A1 (en) | 2001-03-13 | 2006-12-12 | Treatment of tumours |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0100857A SE0100857D0 (en) | 2001-03-13 | 2001-03-13 | Treatment of tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0100857D0 true SE0100857D0 (en) | 2001-03-13 |
Family
ID=20283329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0100857A SE0100857D0 (en) | 2001-03-13 | 2001-03-13 | Treatment of tumors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1379542A2 (en) |
JP (1) | JP2004524325A (en) |
AU (1) | AU2002237613B2 (en) |
CA (1) | CA2440973A1 (en) |
SE (1) | SE0100857D0 (en) |
WO (1) | WO2002072003A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912240A (en) | 1997-04-10 | 1999-06-15 | Loria; Roger M. | 5-androstene 3β, 17α diol as an inhibitor of tumor growth |
DE60324118D1 (en) * | 2002-03-21 | 2008-11-27 | Roger M Loria | ALPHA AED AND BETA-AED REGULATION OF NUCLEAR TRANSCRIPTION, GENERGULATION AND / OR GENE EXPRESSION |
EP1727529B1 (en) | 2004-03-17 | 2016-03-02 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
GB2421183A (en) * | 2004-12-17 | 2006-06-21 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of skin cancers |
CA2670957A1 (en) * | 2006-11-30 | 2008-06-05 | Hunter-Fleming Limited | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
RU2593751C2 (en) | 2011-05-20 | 2016-08-10 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Cb1 receptor antagonists |
SI2925770T1 (en) | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone |
WO2023246940A1 (en) * | 2022-06-24 | 2023-12-28 | Huang Chi Ying | Method of treating a cancer through suppression of growth of cancer stem cells, and downregulation of wnt pathway |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912240A (en) * | 1997-04-10 | 1999-06-15 | Loria; Roger M. | 5-androstene 3β, 17α diol as an inhibitor of tumor growth |
US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
-
2001
- 2001-03-13 SE SE0100857A patent/SE0100857D0/en unknown
-
2002
- 2002-03-11 WO PCT/SE2002/000443 patent/WO2002072003A2/en active Application Filing
- 2002-03-11 AU AU2002237613A patent/AU2002237613B2/en not_active Ceased
- 2002-03-11 CA CA002440973A patent/CA2440973A1/en not_active Abandoned
- 2002-03-11 EP EP02704017A patent/EP1379542A2/en not_active Withdrawn
- 2002-03-11 JP JP2002570963A patent/JP2004524325A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2002237613B2 (en) | 2008-01-03 |
EP1379542A2 (en) | 2004-01-14 |
WO2002072003A3 (en) | 2003-02-20 |
CA2440973A1 (en) | 2002-09-19 |
JP2004524325A (en) | 2004-08-12 |
WO2002072003A2 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003282233A1 (en) | Quinoline derivatives as glucokinase ligands | |
WO2003070163A3 (en) | Prostacyclin derivatives for treating cancer | |
PL309225A1 (en) | Pharmacologically active derivatives of pyridine and methods of obtaining them | |
WO1999046279A3 (en) | INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE | |
MY136761A (en) | Oxazol derivatives | |
AU2003282234A1 (en) | Benzofuran derivates, process for their preparation and intermediates thereof | |
MX9706345A (en) | Benzopyran-containing compounds and method for their use. | |
DK1373215T3 (en) | Gelanamycin derivatives suitable for the treatment of cancer | |
GB0223038D0 (en) | Therapeutic compounds | |
GEP20033140B (en) | Substituted Bicyclic Derivatives Useful as Anticancer Agents | |
TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
JP2005505588A5 (en) | ||
NO954996D0 (en) | Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS | |
NO20050450L (en) | Combination of ZD6474, an inhibitor of vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer | |
SE0100857D0 (en) | Treatment of tumors | |
SE0003476D0 (en) | Compounds | |
AU5705099A (en) | Compounds useful as aicarft inhibitors | |
NO20013414D0 (en) | New use of melagatran | |
ATE360428T1 (en) | ANALGESIC MEDICINAL PRODUCT | |
WO2002064172A3 (en) | Fhit gene therapy prevents tumor development in fhit-deficient mice | |
AU2003281193A1 (en) | Quinazoline derivatives for use in the treatment of cancer | |
WO2002078690A3 (en) | Taxoid anti-tumor agents and pharmaceutical compositions thereof | |
NO20052177L (en) | Use of galantamine and its derivatives for the manufacture of drugs | |
NO20041057L (en) | Prophylactic and therapeutic use of hydroxysteroids | |
MXPA03006359A (en) | Method for treating cancer having greater efficacy and reduced adverse effects. |